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Abstract
Cerebral malaria (CM) is a complex parasitic disease caused by Plasmodium sp. Failure to
establish an appropriate balance between pro- and anti-inflammatory immune responses is
believed to contribute to the development of cerebral pathology. Using the blood-stage PbA
(Plasmodium berghei ANKA) model of infection, we show here that administration of the
pro-Th2 cytokine, IL-33, prevents the development of experimental cerebral malaria (ECM)
in C57BL/6 mice and reduces the production of inflammatory mediators IFN-γ, IL-12 and
TNF-α. IL-33 drives the expansion of type-2 innate lymphoid cells (ILC2) that produce Type-2
cytokines (IL-4, IL-5 and IL-13), leading to the polarization of the anti-inflammatory M2macro-
phages, which in turn expand Foxp3 regulatory T cells (Tregs). PbA-infected mice adoptively
transferred with ILC2 have elevated frequency of M2 and Tregs and are protected from ECM.
Importantly, IL-33-treated mice deleted of Tregs (DEREGmice) are no longer able to resist
ECM. Our data therefore provide evidence that IL-33 can prevent the development of ECM by
orchestrating a protective immune response via ILC2, M2macrophages and Tregs.
Author Summary
Cerebral malaria (CM) caused by the parasite Plasmodium sp. is a fatal disease, especially
in children. Currently there is no effective treatment. We report here our investigation on
the role of a recently discovered cytokine, IL-33, in treating experimental cerebral malaria
(ECM) in the susceptible C57BL/6 mice. IL-33 protects the mice against ECM. The protec-
tion is accompanied by a reduction of Th1 response and the enhancement of type 2 cyto-
kine response. We also found that IL-33 mediates its protective effect by inducing a
population of type 2 innate lymphoid cells (ILC2), which then polarize macrophages to
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alternatively-activated phenotypes (M2). M2 in turn expand regulatory T cells (Tregs)
which suppress the deleterious Th1 response. Our report therefore reveals hitherto
unrecognised mechanisms of the regulation of ECM and provide a novel function of IL-33.
Introduction
Malaria remains a major health problem for humans infected with Plasmodium species. Cere-
bral malaria (CM) is a severe and potentially fatal neurological manifestation of infection and
accounts for approximately one million deaths annually of children in sub-Saharan Africa alone
[1]. CM is characterized by a strong Th1 immune response, with a robust and uncontrolled
production of proinflammatory cytokines (IFN-γ and TNF-α) and chemokines (IP-10/CXCL10,
KC/CXCL1 and MCP-1/CCL2) [2,3] that contribute to vascular leakage and sequestration of
parasitized red blood cells (pRBCs) and leukocytes within the brain blood vessels [4,5]. In
malaria, the balance between pro- and anti-inflammatory cytokines is critical in determining
the outcome of infection, and recent evidences suggest that helminth co-infection may dampen
immunopathological responses to malaria parasite by inducing a protective type-2 response
[6,7]. Studies using murine models of malaria have established that genetic background of the
host affects the development and outcome of ECM. Infection of C57BL/6 mice, which present
a Th1-biased phenotype, with the rodent parasite Plasmodium berghei ANKA (PbA) induces a
fatal cerebral disease characterized by neurological disorders including paralysia, convulsion
and coma. In contrast, BALB/c mice, that present a Th2-biased phenotype, do not develop
neurological complications and die at later stages from high parasitemia and anaemia [8,9].
IL-33, the latest member of the IL-1 cytokine family [10], plays an important role in Th2-
associated immune responses [11,12]. IL-33 has been linked to a number of inflammatory
disorders including allergic asthma, rheumatoid arthritis, allergic rhinitis and ulcerative colitis
[13]. IL-33 binds to a heterodimer receptor composed of ST2 (IL-33R) and IL-1R accessory
protein, leading to the production of IL-4, IL-5, IL-10 and IL-13 from mast cells, eosinophils,
Th2 lymphocytes and the newly discovered population of type 2 innate lymphoid cells (ILC2)
[12]. In vitro, IL-33 has also been shown to synergize with IL-4 to drive the polarization of al-
ternatively-activated macrophages (M2) [14], that secrete high levels of IL-10 and TGF-β. We
hypothesized that IL-33 could divert the deleterious Th1-immune response during infection
and therefore protects mice from ECM.
Results reported here demonstrate that PbA-infected C57BL/6 mice treated with recombinant
IL-33 presented no signs of neurological pathology associated with CM and had reduced produc-
tion of pro-inflammatory cytokines and chemokines. This IL-33-protective effect was mediated by
the activation of ILC2 that produced type 2 cytokines which in turn polarized anti-inflammatory
M2macrophages. Furthermore, M2 macrophages expanded Tregs, the depletion of which abro-
gated the protective effect of IL-33. We therefore present a previously unrecognised role of IL-33
in ECM, and provide evidence that induction of type 2 immunity by an exogenous cytokine
treatment was sufficient to down-regulate the inflammatory Th1 response and ECM induced
by PbA.
Results
IL-33 treatment protects mice from cerebral malaria induced by PbA
To determine whether IL-33 could modulate malaria pathogenesis, we first infected C57BL/6
mice with Plasmodium berghei ANKA (PbA) parasites (104 parasitized red blood cells, pRBC)
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and treated the mice with recombinant murine IL-33 (0.2 mg/mouse/day, intraperitoneally)
starting from day 0. Body weight loss, parasitemia, clinical score and survival were monitored
daily. PbA-infected control mice developed parasitemia, body weight loss and CM symptoms
(head deviation, ataxia and paraplegia) from day 5 post infection, and all mice succumbed to
CM by day 7–8 (Fig. 1A-D). In contrast, mice treated with IL-33 displayed reduced body
weight loss, clinical score and survived up to day 20 post-infection when they were euthanised
due to development of hyperparasitemia (up to 40% parasitemia) (Fig. 1D). This indicates that
IL-33 administration protects mice from ECM but not from malaria-induced hyperparasitemia
and death. Similar results were obtained when the IL-33 treatment began one day after
infection (day +1). Similar results were also obtained with 100× higher PbA infective dose
(S1A-S1B Fig.).
Adherence of parasited red blood cells (pRBC) to the vascular endothelium of organs plays
a key role in the pathogenesis of Plasmodium species allowing the parasite to escape clearance
in the spleen [15]. In vivo imaging using luciferase-expressing PbA confirmed that the parasite
biomass was significantly reduced in IL-33-treated mice indicating that the reduction in
blood parasitemia was not due to an increase of parasite sequestration in the peripheric organs
(Fig. 1E, F).
CM is associated with parasite sequestration into the brain microvasculature and cerebral
hemorrhage that result from excessive systemic inflammation, which involves pro-inflammatory
cytokine production leading to endothelial cell activation and vascular permeability [16].
Using the luciferase-expressing PbA, we found a strong increase in parasite biomass in the
brain of PBS-treated mice on day 7 post-infection (Fig. 1G, H). In contrast, IL-33-treated ani-
mals showed a significant reduction of luciferase activity in the brain, indicating diminished
pRBC accumulation. Histopathological analysis of brains from PBS-treated mice showed
microhemorrhages and cytoadhesion of erythrocytes and leucocytes to the brain vasculature
on day 7. Mice treated with IL-33 displayed markedly fewer hemorrhages and less vessel obstruc-
tion compared to the PBS-treated mice (Fig. 1I, J). Finally, quantitative PCR analysis showed an
upregulation of Icam-1 expression in the brain tissues of PbA-infected PBS-treated mice, that
was absent in IL-33-treated mice (Fig. 1K), consistent with the reduction of cytoadhesion in
IL-33-treated mice compared to the controls.
IL-33 reduces pro-inflammatory cytokine and chemokine production in
PbA-infected mice
To investigate how IL-33 might interfer with the host immune response, we measured the lev-
els of the key Th1 cytokines (IFN-γ, IL-12 and TNF-α), key Th2 cytokines (IL-4, IL-5 and
IL-13), and the regulatory cytokine IL-10 in the serum at various time-points after infection
with PbA. Levels of IFN-γ, IL-12 and TNF-α rose progressively to day 5 in the serum of PBS-
treated mice. In contrast, the levels of these cytokines were significantly reduced in IL-33-treat-
ed mice (Fig. 2A-C). The levels of serum IL-5 were low in the control mice but were strongly
enhanced in IL-33-treated mice, (Fig. 2D). The levels of serum IL-4 and IL-13 were barely de-
tectable in all groups of mice. The concentrations of serum IL-10 also increased in PBS control
mice but were reduced in IL-33-treated mice (Fig. 2E). Early production of the pro-inflammatory
chemokines IP-10/CXCL10, KC/CXCL1 and MCP-1/CCL2 was also reduced in the serum of
IL-33-treated mice compared to PBS-control mice (Fig. 2F-H). We then assessed the expres-
sion of lineage-specific transcription factors in CD4+ T cells purified from the spleen of PbA-
infected mice. The Th1-specific transcription factor Tbet peaked at day 3 of infection in PBS
control mice but was reduced on day 3 and unchanged on day 5 in IL-33-treated mice com-
pared to PBS-treated mice (Fig. 2I). IL-33 did not affect Gata3 expression in purified CD4+
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T cells (Fig. 2J), suggesting that Th2 cells are unlikely involved in IL-33-mediated protection.
T cell-derived Granzyme B (GrmB) is known to drive cytotoxic T cell-mediated cerebral pa-
thology [17]. We therefore determined GrmB expression in splenic CD8+ and CD4+ T cells.
Percentage and frequency of GrmB+CD8+ and GrmB+CD4+ T cells in PbA-infected mice
was markedly increased compared to non-infected mice (Fig. 2K, L). Granzyme B positive
CD8+ and CD4+ T cells were significantly reduced in percentage and number in IL-33-treated
mice compared to PBS-treated control mice (Fig. 2K, L). Together, our results suggest that
IL-33-mediated protection against ECM is likely associated with reduction in the early pro-
inflammatory type-1 response.
Figure 1. IL-33 protects mice from PbA-induced cerebral malaria.C57BL/6 mice were infected i.v. with Plasmodium berghei ANKA (PbA) (104 pRBCs)
and injected i.p. daily with PBS or IL-33 (0.2 μg) from day 0. (A) Kaplan–Meier survival curves (pool of 3 experiments, n = 14–20 per group). (B) body weight
loss (n = 5 per group); Statistical differences are shown for day 7. (C) Clinical score (n = 5 per group). The hatched area indicates ECM related scores. (D)
Time-course analysis of parasitemia (n = 5 per group). (E) Parasite-derived bioluminescence. One representative mouse is shown at each time point.
Radiance (P/Sec/cm2/Sr), color scale Min = 2×106, Max = 5×107. (F) Mean body bioluminescence (n = 5 per group). (G) Mice infected with PbA-Luc were
sacrificed on day 7 and bioluminescence of the brain was recorded. (H) Mean brain bioluminescence per group (n = 6). (I) Representative H&E
histopathology of brain vasculature from PBS- or IL-33-treated mice. Magnification ×400. (J) Severity of brain microvascular obstruction and local
hemorrhage assessed from a whole-brain section (n = 6 per group). (K) Icam-1mRNA expression (relative to Hprt1) in the brain determined by qPCR (n = 6
per group); Data are mean SEM. Representative data from 3 independent experiments were shown. ns, non significant, ***P<0.001.
doi:10.1371/journal.ppat.1004607.g001
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IL-33 induces ILC2 expansion and type 2 cytokine production in
PbA-infected mice
Recently, IL-33 has been found to directly induce ILC2 expansion and cytokine production in
vitro and in vivo [18–20].We therefore analysed the effect of IL-33 on ILC2 in the ECMmodel.
The frequency and number of ILC2 in the spleen of non-infected (NI) or PbA-infected mice
after treatment with PBS or IL-33 were analysed by FACS. A small but consistent percentage of
lineage negative CD45+ST2+ICOS+ cells, corresponding to ILC2 [21], was found in the spleen
of NI mice in the absence of IL-33-treatment. However IL-33-treatment significantly increased
the percentage and number of ILC2 in the spleen in NI and PbA-infected mice compared to
PBS-treated mice (Fig. 3A-C). These cells were negative for lineage markers (CD4, CD11b,
Figure 2. IL-33 reduces pro-inflammatory cytokines and chemokines in PbA-infected mice.C57BL/6 mice were not infected (NI) or infected with PbA
and injected i.p. daily with PBS (open columns) or IL-33 (filled columns) from day 0 for 5 consecutive days. (A-H) Serum IFN-γ, IL-12, TNF-α, IL-5, IL-10,
IP-10, KC and MCP-1 concentrations were determined by ELISA or Multiplex. Mean SEM (n = 5–7 per group). (I-J) Expression of Tbet andGata3mRNA
(relative to Hprt1) in purified splenic CD4+ T cells was analysed by qPCR (n = 3 per group). Intracellular staining of Granzyme B (GrmB) in splenic CD8+ (K)
and CD4+ (L) T cells on day 6. Data are mean SEM (n = 5–7 per group). ns, not significant, *P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g002
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CD11c, NK1.1, CD3e, Ter119, FcεRI, Siglec F, Gr1, CD49b, CD5, F4/80) and positive for the
innate lymphoid cell markers CD127, CD44, Sca-1, IL-1R1 and CD25 (S1C-S1D Fig.). The
proportion of Ki67+ cells among splenic ILC2 was higher in IL-33-treated mice, suggesting that
at least some of these cells proliferated in situ (Fig. 3D). Intracellular staining revealed that
ILC2 from IL-33-treated mice, but not from PBS-treated mice, expressed substantial levels of
IL-4, IL-5 and IL-13 after ex vivo PMA-ionomycin stimulation (Fig. 3E-F). We were unable to
detect IL-4, IL-5 or IL-13 production by CD4+ T cells or FcεR1+ cells. These data demonstrated
that IL-33 not only induced the recruitment and proliferation of ILC2 but further activated
these cells to produce Type-2 cytokines in vivo during PbA infection.
To investigate the potential role of ILC2 in IL-33-driven protection from CM, we sorted
ILC2 and adoptively transferred them into naïve WT mice. One day after ILC2 transfer, mice
were infected with PbA and monitored daily for parasitemia, body weight loss and neurological
symptoms. Two injections of IL-33 (0.2 mg/mouse, i.p.) were given to the recipient mice 30 min
and 24 h after cell transfer. An earlier study has shown that the provision of IL-33 boosts the
survival and cytokine production of the transferred ILC2 cells [22]. A control group infected
with PbA and similarly treated with IL-33 confirmed that IL-33 at this dose and schedule of
treatment was suboptimal and not protective (Fig. 3G, H). While the two control groups devel-
oped severe body weight loss and succumbed to CM by day 7, all the recipient mice given ILC2
exhibited limited clinical disease and survived beyond day 14 (Fig. 3G, H). The parasitemia of
ILC2-transferred mice was reduced within the first week of infection compared to PbA control
group (Fig. 3I). Mice that received only 2 injections of IL-33, exhibited a slight reduction of
parasitemia but nevertheless succumbed to CM by day 7. Histopathology analysis of the brain
on day 7 revealed a significant reduction of microhemorrhages and vessel obstruction in the
ILC2 recipients compared to the control mice (Fig. 3J, K). The cells producing IL-5 and IL-13
in the ILC2 recipient mice are CD4− T cells and not CD4+ T cells (S2A-S2C Fig.), indicating
that they are unlikely to be Th2 cells. These results therefore demonstrate that ILC2 play an im-
portant role in the IL-33-mediated protection against ECM.
IL-33 polarizes M2 macrophages
We then investigated the mechanism by which ILC2 protects mice against ECM. Macrophages
can be divided into specific subsets according to their polarization environment, phenotype,
and function. M1 (classically-activated macrophages) typically produce pro-inflammatory
cytokines, including TNF-α and IL-12, whereas M2 (alternatively-activated macrophages)
have been implicated in immune regulation, phagocytosis, and tissue remodeling [23,24]. As
M2 macrophages are polarized by IL-4 and IL-13, and that these cytokines are produced by
ILC2, we therefore assessed the profile of macrophage polarization in mice infected with PbA
with or without IL-33 treatment.
The percentage and number of CD11b+F4/80+CD11c− cells in the spleen of mice adminis-
tered with IL-33 were significantly elevated compared to that treated with PBS (Fig. 4A-C).
Expansion of CD11b+F4/80+CD11c− cells was accompanied by increased expression of the key
M2 marker (CD206, mannose receptor) and the reduction of the M1 markers (CD86, MHC-II
and CD40) on macrophages recovered from IL-33-treated mice compared to that of the
PBS control mice (Fig. 4D and S3A Fig.). The expression of other M2 markers (Arginase-1,
Ym1/chitinase 3–like 3 and Fizz1/resistin-like α) were also elevated in the spleen whereas
the expression of the key M1 marker, Nos2, was reduced in IL-33-treated mice compared to
that of the PBS control mice (Fig. 4E). Interestingly, mRNA expression of heme oxygenase-1
(Hmox-1), an enzyme that converts heme into carbon monoxide, was significantly increased in
the spleen of IL-33-treated mice compared to PBS-control mice (Fig. 4E). QPCR analysis on
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sorted CD11b+F4/80+CD11c− cells confirmed that splenic macrophages from IL-33-treated
mice, but not from PBS-treated mice, exhibited an M2-polarization status (S3B Fig.). Overall,
our data indicate that IL-33 increases macrophage number in the spleen and promotes their
polarization towards M2 phenotype.
Figure 3. IL-33 expands ILC2 which adoptively protect mice against ECM. C57BL/6 mice were not infected (NI) or infected with PbA and treated daily
with PBS or IL-33 from day 0. Splenic ILC2 were analysed by FACS on day 3. (A) Representative FACS showing % of ICOS+ST2+ cells gated on Lin− CD45+
cells. Cumulative percentage (B) and number (C) of ILC2 per spleen are shown. (D) Percentage of Ki67+ ILC2. Data are mean SEM (n = 5 per group) and
representative of 2 independent experiments. *P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA. (E-F) Total spleen cells were restimulated ex vivo for
4 h with PMA/ionomycin and stained for intracellular cytokines. (E) Dot plots show expression of IL-4, IL-5 and IL-13 by ILC2 (gated on live
Lin−CD45+ICOS+ST2+ cells) on day 3 post-infection. (F) Cumulative data shows mean SEM of cytokine production (n = 5 per group). Data are
representative of 2 independent experiments. (G-K) ILC2 sorted frommice pre-treated with IL-33 were adoptively transferred (2×106 cells, i.v., on day −1) into
naïve C57BL/6 mice which were infected with PbA (104 pRBCs, i.v., on day 0). The recipients were given 2 injections of IL-33 (0.2 μg, i.p.) 30 min and 24 h
after cell transfer. Survival (G), body weight loss (H) and parasitemia (I) were assessed daily. ***P<0.001 between PbA and PbA+IL-33+ILC2 groups;
#P<0.05 between PbA and PbA+IL-33 groups. (J) Representative H&E staining of brain sections on day 7, magnification ×400. (K) Vessel obstruction scores
in the brain (same colour code as in F). Data are mean SEM (n = 5 per group). ***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g003
IL-33 Protects from ECM
PLOS Pathogens | DOI:10.1371/journal.ppat.1004607 February 6, 2015 7 / 21
ILC2 promote M2 macrophage polarization
Since IL-33 alone is not sufficient to fully differenciate M2 macrophages [14], we investigated
the potential role of ILC2 in M2 polarization in vitro. Purified ILC2 were co-cultured in a
transwell culture with bone marrow-derived macrophages (BMDM) in culture medium alone
Figure 4. IL-33 polarizes M2macrophages in PbA-infected mice.C57BL/6 mice were not infected (NI) or
infected i.v. with PbA and treated daily for 5 days with PBS or IL-33 and spleen cells were harvested at
indicated time points and analysed. (A) Representative dotplots showing percentage of CD11b+F4/80+ cells
among total splenocytes. (B) Percentages and (C) numbers of CD11b+F4/80+CD11c−macrophages in the
spleen. (D) Mean Fluorescence Intensity (MFI) of CD206, CD86, MHC-II and CD40 on macrophages (n = 5
per group). (E) Expression (relative to Hprt1) of Arg-1, Ym1, Fizz1, Nos2 andHmox-1mRNA in the spleen on
day 5. Data are mean SEM, representative of 2 independent experiments. ns, not significant, *P<0.05,
**P<0.01, ***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g004
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(M0) or supplemented with IL-4 (M2-polarizing conditions). After 24 h, BMDM were
harvested and analysed by qPCR for M2 markers. Under the M0 conditions, BMDM alone did
not expressed detectable M2 markers. However, when co-cultured with ILC2, a low level of
Arginase-1, Ym1 and Fizz1 RNA became detectable (Fig. 5A). Under the M2-polarizing condi-
tions, these markers were clearly detected and markedly enhanced by the presence of ILC2
(Fig. 5A). Functionally, the polarized M2 macrophages displayed enhanced capability to uptake
dextran-FITC or pRBC compared to unpolarized macrophages (S3C-S3D Fig.).
Since ILC2 proliferation and cytokine production are IL-7- and IL-33-dependent [25], we
determined the effect of activated-ILC2 on BMDM. To avoid any direct effect of IL-33 on
BMDM, we used ST2-deficient BMDM.When cultured alone, ST2-deficient BMDM did not
express any M2 markers even when IL-33 or IL-33 + IL-7 were added to the culture. In the
presence of ILC2, the expression of Arginase-1 and Ym1 in the ST2-deficient BMDM was in-
creased, and the expression of these markers were further enhanced by the addition of IL-33
alone or in combination with IL-7 (Fig. 5B), suggesting that activated-ILC2 can produce cyto-
kines involved in M2 polarization. The level of Fizz1 expression was high in the presence of
ILC2 alone and was reduced in the presence of IL-33/IL-7. The reason of this reduction is not
clear but could be due to over-stimulation of Fizz1 expression. We then analysed the produc-
tion of Th2 cytokines by ILC2 in vitro. ILC2 alone (without BMDM) were able to produce low
levels of IL-4, IL-5 and IL-13 in the culture supernatants. This production was markedly increased
after stimulation by IL-33 and IL-7 (Fig. 5C). Flow cytometry analysis of ILC2 confirmed that
ILC2 in the culture produced IL-4 and IL-13 and the production was further enhanced by the
presence of IL-33 + IL-7 (Fig. 5D, E). The polarized M2 did not produce detectable amount of
IL-33.
We next investigated the role of ILC2 in the polarization of M2 in vivo. Sorted ILC2 were
adoptively transferred to naïve C57BL/6 mice which were infected with PbA and treated with
suboptimal doses of IL-33, as described in Fig. 3F. The protected ILC2 recipients had increased
expression of Arginase-1, Ym1 and Fizz1 in their spleen cells (Fig. 5F), indicating that ILC2 are
involved in M2 polarization in vivo. Together, our data showed that IL-33-induced ILC2 can
effectively drive M2 polarization in vitro and in vivo.
The role of ILC2, M2 and Tregs in IL-33-mediated protection against
ECM
Previous studies have implicated Tregs to limit disease and immunopathology in the PbA-
induced models of ECM [26–28] and IL-33 has been shown to induce Tregs in vivo [20,29–31].
We therefore explored the impact of IL-33, ILC2 and M2 macrophages on Tregs in the ECM
model. First, we noted that the level of Foxp3message in sorted splenic CD4+ T cells was in-
creased in IL-33-treated mice during PbA-infection compared to PBS-treated mice. The per-
centage and total number of Foxp3+ splenic CD4+ T cells in the mice infected with PbA were
significantly increased by the treatment with IL-33 (Fig. 6A-B). We then determined the effect
of adoptively transferred ILC2 in the induction of Tregs in vivo (as described in Fig. 3F).
Suboptimal doses of IL-33 led to increased frequency of Foxp3+ cells among splenic CD4+
suggesting that IL-33 alone could induce Treg polarization which was however not sufficient
to protect the mice from ECM (see Survival curve and Clinical Score in Fig. 3F). However,
the spleens of IL-33-treated PbA-infected mice given ILC2 contained significantly higher
frequency of Foxp3+ among CD4+ T cells compared to those not given ILC2 (Fig. 6C-D). To
demonstrate a direct link between M2 and Tregs, we co-cultured purified CD4+CD25+ T cells
with M2 in the presence of soluble anti-CD3. M2 significantly expanded the Foxp3+ Tregs
(Fig. 6E). We also cultured CD4+CD25− T cells under the inducible Treg (iTregs) conditions
IL-33 Protects from ECM
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Figure 5. ILC2 promote M2macrophage polarization. (A) BMDM from C57BL/6 mice were cultured in the
lower chamber of a 24-transwell plate in complete medium alone (M0) or supplemented with IL-4 (M2). In
some experiments ILC2, sorted from naïveWTmice pre-treated with IL-33, were added to the upper
chamber. After 48 h, BMDMwere collected and assayed for the expression of M2 markers by qPCR (relative
IL-33 Protects from ECM
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(plate-bound anti-CD3, soluble anti-CD28 + TGF-β, anti-IL-4 and anti-IFN-γ) in the presence
or absence of M2. M2 markedly enhanced the development of iTregs as determined by the
frequency of Foxp3+CD4+ T cells (Fig. 6F).
We then investigated whether the Treg population was involved in IL-33-mediated protec-
tion from ECM. For this purpose, we used DEREG mice, in which administration of diphtheria
toxin (DT) leads to specific-depletion of Tregs due to expression of DT receptor-enhanced Gfp
under the control of the Foxp3 promoter [32]. DEREG mice were infected with PbA and treat-
ed daily with PBS or IL-33 from the start of infection. DT was administered intraperitoneally
every second day from day 1. Treg depletion in IL-33-treated DEREG mice was confirmed in
the peripheral blood by flow cytometry (Fig. 7A). As previously reported [33], Treg depletion
in PBS-treated DEREG mice has no effect on the parasitemia and survival. PbA-infected
DEREG mice treated with PBS died on day 7 with severe ECM (Fig. 7B, C). IL-33-treated in-
fected DEREG mice did not develop CM and died at later stages from hyperparasitemia. In
contrast, IL-33-treated PbA-infected DEREG mice that received DT developed cerebral disease
and died by day 7. IFN-γ and Granzyme B production by splenic CD8+ T cells, which were
significantly reduced in the IL-33-treated mice, was partly reversed in IL-33-treated mice after
DT administration (Fig. 7D-E). In addition, serum levels of IFN-γ and IL-12, which were
markedly reduced in IL-33-treated mice, were also restored when Tregs were depleted (Fig. 7F).
Together these results indicate that IL-33 induces ILC2 which in turn polarize M2 macro-
phages. M2 can expand Tregs which mediate the suppression of the Th1 response, which is
critical to ECM pathogenesis (Fig. 8).
Discussion
Data reported here reveal a previously unrecognised role of IL-33 in the protection against
cerebral malaria by reducing pro-inflammatory cytokines and chemokines production and in-
hibiting vascular sequestration of infected erythrocytes and inflammatory cells in the brain.
Furthermore, we provide a plausible mechanistic pathway by which IL-33 induces the expan-
sion of ILC2 which in turn promote the polarization of M2 macrophages and Tregs that are
critical for the protection against ECM.
ILC2 have emerged as key players in experimental and clinical diseases [34]. They expand
strongly in vivo in response to IL-25 and IL-33, and represent the predominant early source of
IL-5 and IL-13 during allergic inflammation and worm infection [25,35]. In PbA-infected
mice, exogenous IL-33 induces a robust expansion and mobilization of ILC2 which have the
potential to produce IL-4, IL-5 and IL-13. Adoptive transfer of ILC2 markedly ameliorated
ECM. IL-33 administration following ILC transfer was necessary to induce the protection, like-
ly because ILC2 require IL-33 stimulation to expand and produce sufficient amount of type 2
cytokines [22]. However, the possibility that IL-33 may also act on other cell types that partici-
pate in the protection against ECM cannot be excluded. In vitro, we confirmed that ILC2 can
polarize BMDM into M2 macrophages in a cell-cell contact independant manner. IL-33
to Hprt1). (B) ST2-deficient BMDMwere co-cultured in transwell plates as above with WT ILC2 in the
presence of IL-33 alone or in combination with IL-7. After 48 h, BMDMwere collected and assayed for the
expression of M2 markers by qPCR (relative to Hprt1). Type 2 cytokines in the supernatants of ILC2 cultured
in the presence of IL-33 or IL-33 + IL-7 were determined by ELISA (C), or by FACS (D, E). Data are
mean SEM (n = 3 per group), representative of two independent experiments, *P<0.05, **P<0.01,
***P<0.001 by two-tailed ANOVA. (F) ILC2 sorted frommice pre-treated with IL-33 were adoptively
transferred (2×106 cells, i.v., on day −1) into naïve C57BL/6 mice which were infected with PbA (104 pRBCs,
i.v., on day 0). The recipients, were given 2 injections of IL-33 (0.2 μg, i.p.) 30 min and 24 h after cell transfer.
Expression of Arg-1, Ym1 and Fizz1mRNA in the spleen was measured by qPCR (relative toHprt1) on day 7.
Data are mean SEM (n = 5 per group) *P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g005
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increased production of IL-4 and IL-13 by ILC2, which can synergize to polarize M2 macro-
phages [14,36]. This is supported by our data showing that adoptively transferred ILC2 can
collaborate with IL-33 to polarize M2 in vivo.
M2 macrophages exhibit potent anti-inflammatory properties and play important roles in
parasite clearance, tissue repair and remodeling [37]. One of the proposed mechanism for the
immunomodulatory role of M2 macrophages is the competition between Arginase-1 (express-
ed by M2) and iNOS (expressed by M1) for the subtrate L-Arginine [37]. Another mechanism
is the production of carbon monoxide (CO) by heme-oxygenase-1 (HO-1), an enzyme which
has been shown to be preferentially expressed in CD206+ M2 macrophages [38]. HO-1
Figure 6. IL-33, ILC2 and M2 induce Tregs. (A-C) C57BL/6 mice were infected i.v. with PbA and treated daily with PBS or IL-33 from day 0. (A) Relative
expression (% ofHprt1) of Foxp3+ mRNA in purified CD4+ cells from the spleen. (B) percentage of Foxp3+ cells gated on CD4+ cells and number of
Foxp3+CD4+ cells in the spleen. Data are mean SEM (n = 5 per group), representative of at least 2 independent experiments. *P<0.05, **P<0.01,
***P<0.001 by two-tailed ANOVA (C-D) ILC2 sorted frommice pre-treated with IL-33 were adoptively transferred (4×106 cells, i.v., on day −1) into naïve
C57BL/6 mice which were infected with PbA (104 pRBCs, i.v., on day 0). The recipients were given 2 injections of IL-33 (0.2 μg, i.p.) 30 min and 24 h after cell
transfer. Spleen cells were harvested on day 7 and analysed by FACS for Foxp3 expression gated on CD4+ cells. Data are mean SEM (n = 5 per group).
*P<0.05, **P<0.01, ***P<0.001 by two-tailed ANOVA. (E, F) M2 induce Tregs in vitro. (E) CD4+CD25+ T cells from naïve C57BL/6 mice were co-cultured
with or without BMDM-derived M2 for 2 days and analysed for Foxp3 expression by FACS gated on live CD4+ cells. (F) CD4+CD25− T cells from naïve
C57BL6 mice were cultured under iTreg polarizing conditions in the presence or absence of BMDM-derived M2 for 2 days and Foxp3 expression was
analysed by FACS gated on live CD4+ cells. Data are mean SEM of 3 experiments. *P<0.05 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g006
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catalyzes the degradation of heme into biliverdin, iron and CO [39]. Here, we found that
IL-33-treated mice expressed higher levels of HO-1 in the spleen. Free heme release during
Plasmodium spp. infection contributes to blood brain barrier disruption and ECM pathogenesis
[40]. CO production by HO-1 has been shown to suppress PbA-induced ECM by inhibiting
blood brain barrier disruption, reducing adhesion molecule expression in the brain microvas-
culature and CD8+ T cell sequestration in the brain [40]. The role of IL-33 in the induction of
CO via HO-1 merits further investigation.
Tregs expansion by IL-2/anti-IL-2 complexes in vivo has been implicated to protect mice
against T cell-mediated immune pathology in PbA-induced ECM [28], although direct evi-
dence for a role of Tregs in ECM remains elusive. We and others have shown earlier that IL-33
administration leads to Treg induction [20,29–31,41]. Here, we provide data supporting that
IL-33-mediated induction of Tregs in PbA-infected mice involves the activity of ILC2 and M2
macrophages. We also show that M2 expand natural Tregs and inducible Tregs in vitro. Impor-
tantly, Tregs depletion abrogated the protective effect of IL-33 in ECM by reducing the Th1
cell response. These results therefore demonstrate a cascade of events leading to the protection
of ECM by IL-33 (Fig. 8). The detailed mechanism by which Tregs suppress effector T cells, the
major immunopathological mediators of ECM, remains to be explored.
It is important to note that IL-33-treated mice produced minimal amount of IL-10 during
PbA-infection (Fig. 2E). Furthermore, administration of anti-IL-10 monoclonal antibody in
IL-33-treated mice did not affect the protection conferred by IL-33 (S4A-S4B Fig.). Therefore,
Figure 7. IL-33-mediated protection against ECM is Treg-dependent.DEREGmice were infected with PbA (105 pRBC, i.p.) and daily treated with PBS or
IL-33 for 5 consecutive days. Where indicated, mice received diphteria toxin (DT, 1 μg, i.p.) every second day from day 1. (A) Treg depletion was assessed in
blood leukocytes on day 5 of infection by FACS on GFP-Foxp3 gated on CD4+ T cells, representative of 5 mice. (B) Survival (Kaplan–Meier survival curves)
and (C) clinical score (hatched area indicates ECM related scores) of DEREGmice treated with PBS or IL-33 with or without DT (n = 4–5 per group) are
shown. (D-E) Percentage of IFN-γ+ and Granzyme B+ (GrmB) CD8+ T cells in the spleen on day 5 post-infection was determined by FACS. (F) Serum IFN-γ
and IL-12 concentrations were determined by ELISA (day 5) (n = 5 per group). Data are mean SEM representative of 2 experiments, *P<0.05, **P<0.01,
***P<0.001 by two-tailed ANOVA.
doi:10.1371/journal.ppat.1004607.g007
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it is unlikely that M2- or Tregs-produced-IL-10 participates to ECM protection by IL-33. This
is consistent with an earlier report which shows CTLA4-dependent but IL-10-independent
protection against ECM [28].
IL-33-treated mice, though consistently showed significant reduction in parasitemia at
the early stage of infection (day 5–7) compared to untreated mice, were unable to clear the
parasite and eventually died at later stage from hyperparasitemia. IL-33-mediated protection
was achieved when the cytokine was given relatively early after infection and delaying treat-
ment by 48 h failed to control the disease. This observation suggests a fine temporal interplay
between the protective T cell response against the parasite and the anti-inflammatory response
during PbA infection. Spleen is a key site for removal of pRBC during malaria through pro-
duction of reactive oxygen species and phagocytosis by activated macrophages [42]. More-
over, it has been shown that Flt3L-induced CD11bint F4/80+ red pulp macrophages, which
ressemble the macrophages induced by IL-33, displayed higher phagocytic activity and con-
tributed to parasite clearance in PbA-infected mice [43]. Here, we observed that polarized
M2 macrophages showed enhanced capacity in dextran-FITC or pRBC uptake compared to
unpolarized macrophages (S3C-S3D Fig.). Therefore, the initial reduced parasitemia observed
in our model could be explained by local activation and proliferation of red pulp macrophages,
which might contribute to the parasite killing. Although it is possible that the low parasitemia
contributed to IL-33-mediated protection by reducing PbA antigenic stimulation, it is unlikely
an influential mechanism since we found that IL-33 treatment was still equally protective
in mice infected with a 100× higher dose of pRBC which displayed a parasitemia> 5%
(S1A-S1B Fig.).
IL-33 can directly stimulate eosinophil differentiation and survival [44]. Eosinophil granules
contain cytotoxic, highly basic proteins, including the eosinophilic cationic protein that has
been shown to inhibit P. falciparum in culture [45]. In our model, although the percentage and
number of splenic eosinophils were augmented by 6 folds in IL-33-treated mice compared to
untreated mice, eosinophil depletion using anti-Siglec-F antibody did not affect IL-33-mediated
Figure 8. Schematic representation of the pathways by which IL-33 attenuates ECM. Arrows represent
activation/promotion; dotted blunted arrows = proposed mechanism of suppression.
doi:10.1371/journal.ppat.1004607.g008
IL-33 Protects from ECM
PLOS Pathogens | DOI:10.1371/journal.ppat.1004607 February 6, 2015 14 / 21
protection during PbA infection (S4C-S4G Fig.) suggesting that eosinophils are unlikely an in-
fluential mechanism in IL-33-mediated protection against ECM.
Increased number of CD4+CD25+Foxp3+ Tregs have been observed in humans infected
with Plasmodium falciparum [27,46,47]. It would be of considerable interest to investigate if
the observation reported here is also applicable to clinical cerebral malaria.
Materials and Methods
Animals
Female C57BL/6 mice (8–10 weeks old) were obtained from Charles River UK Ltd. ST2−/−
female mice (on the C57BL/6 genetic background) were originally provided by Dr. Andrew
McKenzie (Medical Research Council Laboratory of Molecular Biology, Cambridge,U.K.) and
bred in-house in a pathogen-free facility at University of Glasgow. DEREG mice (on the
C57BL/6 genetic background, originally provided by Dr. Tim Sparwasser, Hannover Medical
School, Germany) were bred at Transgenose Institute animal facility (UPS44 CNRS, Orleans,
France). Mice under procedure were kept in polyethylene boxes with free access to food and
water, and subjected to 12 h light-dark cycles. All experiments were performed in accordance
with the UK Home Office guidelines and within the terms of the Project License (PPL 70/7293)
granted for this work under the Animals (Scientific Procedures) Act 1986. All efforts were
made to minimize the number of animals used and their suffering.
Experimental infection
C57BL/6 red blood cells infected with Plasmodium berghei ANKA parasites expressing a green
fluorescent protein (PbA GFPcon 259cl2, MRA-865, deposited by CJ Janse and APWaters)
were stored in liquid nitrogen and thawed and passed into wild-type mice that served as para-
site donor. All mice, unless otherwise stated, were inoculated intravenously (i.v.) into the tail
vein with 1×104 parasitized red blood cells (pRBC). Parasitemia was monitored daily (from day
4) by flow cytometry using the FL3 channel (PbA-GFP) and TER-119 APC (erythrocytes) in a
BD FACScalibur cytometer (BD Biosciences). Clinical score was assessed using the following
clinical scale: 1 = no signs; 2 = ruffled fur and/or abnormal posture; 3 = lethargy; 4 = reduced
responsiveness to stimulation and/or ataxia and/or respiratory distress/hyperventilation; and
5 = prostration and/or paralysis and/or convulsions. All animal that reachs stage 4 developped
ECM. Recombinant murine IL-33 (Biolegend) was injected intraperitoneally (0.2 mg/mouse/
200 ml) daily, routinely from the beginning of infection (day 0). As a control for IL-33 effects,
non-infected (NI) mice also received IL-33 for 5 consecutive days. For some experiments, mice
were administered with anti-Siglec F (MAB17061, R&D Systems, 50 mg daily) or anti-IL-10
(MAB417, R&D Systems, 40 mg daily) or appropriate isotype control Abs.
Bioluminescence imaging with IVIS
Mice infected with the transgenic PbA strain that constitutively expresses luciferase (PbA-luc,
gift of Dr. APWaters, Glasgow, UK) were imaged using an IVIS Imaging 100 system (Xenogen
Corp.) Mice were injected intraperitoneally with D-luciferin (PerkinElmer, 150 mg/kg in
DPBS) and anesthetized in 5% isoflurane/1L O2.min−1 atmosphere. The animals were
then placed in the imaging chamber of the IVIS and anesthesia was maintained using 2%
isoflurane/0.2L O2 per mouse min
−1 atmosphere. Bioluminescence (photons per second per
square centimeter per steridian) was monitored over a 20 min period in previously defined re-
gions of interest (ROI). Exposure times varied between 0.5 and 1 min, depending on signal in-
tensity. To standardize imaging and to allow comparison between mice, the images presented
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in the figures were taken once luminescence plateaued. For brain bioluminescence imaging,
mice were sacrificed on day 7, perfused with 20 ml ice-cold PBS and the whole brains were
excised and imaged ex vivo as described previously [48]. To enhance the signal and avoid desic-
cation, 100 ml D-luciferin (150 mg/ml) was pipetted onto the surface of each brain 5–10 min
prior to imaging.
Histology
After intracardiac perfusion with 20 ml ice-cold PBS the brain was removed, fixed with 4%
neutral phosphate-buffered formalin (Merck) and embedded in paraffin. The tissue were cut
into 4 mm sections and stained with hematoxylin-eosin (H&E) following standard procedures.
Brain microvascular obstruction in coronal brain sections was scored by two independent ob-
servers blinded to the experimental groups using a Nikon Eclipse E400 microscope at ×400.
For each brain, fields containing vessels were scored using a semi-quantitative scale (0–5)
according to the severity of obstruction and the presence of microhaemorrhages: 0, no
obstruction; 1, only small vessels obstructed; 2, presence of leukocytes attached to the
endothelium; 3, partial obstruction, presence of leukocytes and RBC; 4, total obstruction,
without haemorrhages; 5, total obstruction with haemorhages. Data are presented as the
average score for each brain.
Real-time PCR
Brains and spleens were excised at indicated time-points and preserved in RNAlater (Qiagen).
CD4+ T cells were purified from total splenocytes at indicated time-point by negative selection
(AutoMACS, Miltenyi Biotec) with 85–90% purity. After homogenization in TRIzol (Sigma-
Aldrich), total RNA was extracted with an RNeasy Mini kit (Qiagen). cDNA was synthesized
using M-MLV Reverse Transcriptase (Promega). The quantitative RT-PCR (qPCR) assays
were performed using TaqMan Real-Time PCR Master Mix in an ABI PRISM 7500 Fast Se-
quence Detection System (Applied Biosystems). Relative expression levels were calculated as
ΔCt values by normalizing Ct values of target genes to Ct values of hypoxanthine phosphoribosyl
transferase-1 (Hprt1). Data are represented as relative % ofHprt1 expression. All primers were
purchased from Applied Biosystems (TaqMan Gene Expression Assay).
Flow cytometry analysis
Cells were first blocked with FcγR blocker and stained with fluorochrome labeled Abs or
their corresponding isotype controls. Abs were purchased from BD Bioscience, Biolegend or
eBioscience. The following Abs were used: anti-ST2 (DJ8), anti-CD45 (30-F11), anti-ICOS
(C398.4A), anti-CD11b (M1/70), anti-F4/80 (BM8), anti-CD11c (N418), anti-CD40 (1C10),
anti-CD206 (C068C2), anti-CD86 (GL1), anti-MHC-II (M5/114.15.2), anti-IL-4 (11B11), anti-
IL-5 (TRFK5), anti-IL-13 (eBio13A), anti-Granzyme B (NGZB). For intracellular cytokine
staining, cells were incubated for 4 h with phorbol-12-myristate-13-acetate (50 ng/ml; Sigma-
Aldrich), ionomycin (750 ng/ml; Sigma-Aldrich) and GolgiStop (1 ml/ml; BD Biosciences).
After surface staining, cells were fixed and permeabilized with BD Fixation/permeabilization
kit (BD Biosciences) and stained for intracellular cytokines. For all experiments, cells were
stained with a Live/Dead Fixable dye (Molecular Probes) to allow gating on viable cells. Data
were acquired using a Beckman Coulter CyAn ADP (Beckman Coulter, USA). Gating strategy
and analysis were performed using the FlowJo software (treeStar Software, USA) and shown in
S1C Fig.
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ILC2 sorting and adoptive transfer
To induce ILC2 in vivo, naive C57BL/6 mice were inoculated intranasally with 1 mg recombi-
nant IL-33 (BioLegend) on five consecutive days. Lung tissue was digested with Liberase TL
(Roche, 0.2 mg/ml) and DNAse I (Sigma, 0.5 mg/ml) for 45 min at 37°C under rotation. Total
lung cells were stained with lineage cocktail Abs (anti-CD3ε, anti-CD11b, anti-CD11c, anti-
NK1.1, anti-siglec F, anti-FcεRI, anti-B220), anti-CD45, anti-ST2 and anti-ICOS Abs for 30
min at 4°C. ILC2 were sorted by FACSAria (BD Biosciences) (purity>98%). ILC2 were defined
as CD45+ICOS+ST2+ lymphoid cells negative for lineage markers as described previously [18].
For adoptive transfer, 2×106 freshly purified ILC2 were injected i.v. to naive C57BL/6 mice,
which were infected i.v. with 104 pRBC 24 h later. Mice were then treated with IL-33 (0.2 mg,
i.p.) 30 min and 24 h after cell transfer.
Bone Marrow Derived Macrophages/ILC2 co-culture and phagocytosis
assay
Bone marrow cells were harvested from femur bones of C57BL/6 WT or ST2-deficient mice
and cultured in petri dishes in complete medium [RPMI-1640 supplemented with 10% (vol/vol)
FCS (LONZA), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin] containing
25% L929 cell-conditioning medium as a source of macrophage colony-stimulating factor
(M-CSF) to differentiate into bone marrow-derived macrophages (BMDM). BMDM were
harvested on day 6 and co-cultured (106 cells) in the lower chamber of a 24-well transwell plate
(0.4 mM porous membrane, Corning) under M0 polarizing conditions (complete medium
only) or M2 polarizing conditions (+ 10 ng/ml IL-4). In some experiments, 2×105 freshly
sorted ILC2 were added in the upper chamber of the transwell. Cells from the lower chamber
were collected for RNA analysis after 24 h co-culture.
For phagocytosis assay, polarized M0 or M2 (from BMDM) were plated at 106 cells/ml and
incubated overnight in complete medium. FITC-labeled Dextran (Sigma, 1 mg/ml) or PbA-
GFP-parasitized RBC (ratio macrophage:pRBC, 1:100) were then added and the cells were in-
cubated at 4°C (controls) or 37°C for 30 min. Cells were harvested, washed and analyzed by
FACS (Beckman Coulter CyAn ADP). At least 20,000 events were collected and data were ana-
lyzed by FlowJo software, and changes were presented as percentage of FITC+ or GFP+ cells.
Tregs/macrophages co-cultures
CD4+CD25+ T cells were purified (AutoMACS, Miltenyi) from the spleen and lymph nodes
of naïve C57BL/6 mice and cultured (5×105 cells/ml) with equal number of BMDM-derived
M2 for 2 days. Foxp3 expression was determined by FACS gated on live CD4+ cells. In some
experiments, CD4+CD25− T cells from naïve C57BL/6 mice were cultured (5×105 cells/ml)
for 2 days under iTreg polarizing conditions (3 mg plate-bound anti-CD3, 1.5 mg soluble
anti-CD28 + 10 ng/ml TGF-β, 10 mg/ml anti-IL-4 and anti-IFN-γ) in the presence or absence
of equal number of M2. Foxp3 expression was determined by FACS gated on live CD4+ cells.
ELISA and multiplex
ELISA for serum IL-13 (Ebioscience), IL-4, IL-5, CXCL1, CXCL10, CCL2 (all from R&D Sys-
tems) were performed following the manufacturer’s instructions. Sensitivity of the assays was
between 20 and 40 pg/ml. Concentrations of serum IFN-γ, IL-4, IL-5, IL-10, IL-12 and TNF-α
were determined using a multiplex mouse cytokine assay (Invitrogen) according to the manu-
facturer’s instructions using a Luminex 200 reader (Luminex Corp.).
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Statistical analysis
Comparisons between 2 groups were performed using a 2-tailed unpaired Student’s t test. Mul-
tiple groups were compared using a 2-way ANOVA followed by a Bonferroni’s post-test. Val-
ues for all measurements are expressed as mean SEM. P<0.05 was considered statistically
significant. Data are representative of at least 3 separate experiments unless otherwise stated in
the legend. Statistical analysis were performed using GraphPad Prism 5.0. (GraphPad Software).
Supporting Information
S1 Fig. IL-33 protects mice from high dose PbA-infection. (A, B) C57BL/6 mice were in-
fected with high dose of PbA (106 pRBCs, i.v.) and treated with PBS or IL-33 (0.2 mg/mouse,
i.p.) from day 0. Survival (A) and parasitemia (B) were assessed daily. Data are mean SEM
(n = 5 per group), representative of two independent experiments. (C, D) Characterization of
ILC2. C57BL/6 mice were injected intraperitoneally with 0.2 mg IL-33 for 4 consecutive days to
induce ILC2 expansion and activation. Spleen were collected 24 h after the last IL-33 adminis-
tration, digested and stained with DAPI, lineage cocktail antibodies, and anti-CD45, ICOS and
ST2 antibodies. (C) Gating strategy for sorting live ILC2. (D) Sorted ILC2 were further stained
with CD127, CD44, Sca1, CD25, IL-1R1, CD4, Gr1, CD49b, CD5 and F4/80 antibodies (empty
histograms) or isotype control antibodies (grey histograms).
(TIF)
S2 Fig. Th2 cells are not the main source of type 2 cytokines in our system. FACS-sorted
ILC2 were adoptively transferred into naïve C57BL/6 mice on day −1. Recipients were given
2 injections of IL-33 (0.2 mg/mouse, i.p.) 30 min and 24 h after cell transfer and infected with
PbA one day after cell transfer. Spleen cells were harvested from the recipients on day 7 after
infection and analysed by FACS for IL-5+/CD4+ cells (A) or IL-13+/CD4+ cells (B). Only the
group given IL-33 + ILC2 showed significant level of IL-5+ and IL-13+ cells which were express-
ed by CD4− cells and not CD4+ cells. (C) Back-gating strategy showing that IL-5-producing cells
were Lin− CD45+ ICOS+ and ST2+. Data are mean SEM (n = 4–5 mice), ns, not significant,
P<0.05, P<0.01,P<0.001 by two-tailed ANOVA.
(TIF)
S3 Fig. (A, B) IL-33 polarizes M2 macrophages in vivo. C57BL/6 mice were infected with
PbA and treated with IL-33 daily for 5 days from day 0. (A) Spleen cells were harvested and
analysed for M2/M1 markers by FACS. Representative histograms are shown for CD206,
CD86, MHC-II and CD40. (B) Q-PCR analysis of FACS-sorted CD11b+F4/80+CD11c− for the
expression of Arg-1, Ym1, Fizz1 andHmox-1mRNA (% of Hprt1). (C, D) Functional analysis
of polarized M2. Bone marrow-derived macrophages were cultured with medium alone (M0)
or in medium supplemented with IL-4 for 24 h (M2). The polarized cells were then cultured
with dextran-FITC (C) or parasitized red blood cells (GFP-expressing PbA) (D) at 4 or 37°C
for 30 min. The cells were then analysed for FITC or GFP by FACS. Data are mean SEM
(n = 3 mice), ns, not significant, P<0.001 by two-tailed ANOVA.
(TIF)
S4 Fig. IL-33-mediated protection against ECM is independent of IL-10 or eosinophils.
C57BL/6 mice were infected with PbA and treated with IL-33 daily from day 0–5. The mice
also received intraperitoneally from day 1 anti-IL-10 antibody (40 mg daily) (A, B), anti-Siglec
F antibody (50 mg daily) (C-G), or isotype-matched normal IgG. (A) Kaplan–Meier survival
curves and (B) Parasitemia of mice treated with anti-IL-10 (n = 5 mice per group). (C-D) IL-33
induced significant level of eosinophils (CD11b+SiglecF+) in the spleen 5 days after infection as
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determined by FACS. These eosinophils were largely ablated by the treatment with anti-Siglec
F antibody (E). (F) Kaplan–Meier survival curves and (G) Parasitemia of mice treated with
anti-Siglec F antibody. Data are mean SEM (n = 5 mice per group), P<0.001 compared
to PBS-treated controls.
(TIF)
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